We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





PHASE Scientific Launches RNA Extraction Kit for COVID-19 Test

By LabMedica International staff writers
Posted on 10 Apr 2020
PHASE Scientific (Hong Kong) has commercially launched the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease. More...
PHASIFY VIRAL purifies and concentrates viral RNA in patient viral transport media samples. This novel technology outperforms conventional solid phase extraction methods in RNA yield and concentration.

PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.

PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.

“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.

Related Links:
PHASE Scientific


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.